摩罗丹浓缩丸治疗慢性萎缩性胃炎(胃阴不足兼胃络瘀血证)的前瞻性随机对照临床试验

目的评价摩罗丹浓缩丸治疗慢性萎缩性胃炎(chronic atrophic gastritis,CAG)的安全性及有效性。方法采用随机阳性药物平行对照临床试验设计,共纳入48例CAG受试者,随机分为摩罗丹浓缩组(简称试验组n=24)和摩罗丹蜜丸组(简称对照组n=24),疗程3月。结果试验组与对照组疗效比较,胃脘胀满愈显率分别为40.9%vs27.3%,总有效率分别为72.7%vs68.2%(P均>0.05),胃脘痛愈显率分别为54.5%vs40.9%,总有效率分别为72.7%vs72.7%(P均>0.05);中医证候疗效比较,两组愈显率分别为9.1%vs0%,总有效率分别为86.4%vs81.8%(P均>0.05)。胃镜复查有效率为31.8%vs18.2%(P均>0.05),病理复查炎症、萎缩、肠化的有效率分别为36.4%vs36.4%;54.6%vs63.6%;18.2%vs27.3%(P均>0.05)。两组之间均无不良反应发生。结论摩罗丹浓缩丸治疗CAG(胃阴不足兼胃络瘀血证)安全有效。     

当归拈痛丸的鉴别及黄芩苷的测定

目的 建立当归拈痛丸的鉴别和含量测定的方法.方法 采用TLC法对处方中的当归、苦参、苍术、葛根、羌活等进行定性鉴别;采用HPLC法测定黄芩中黄芩苷的含量.结果 TLC能检出处方中当归、苦参、苍术、葛根、羌活等;HPLC测定时,黄芩苷0.080～0.401 μg与峰面积呈良好的线性关系(r=0.9998),平均回收率为98.28%,RSD:1.01%.结论 所建方法准确可靠,能有效控制药品的质量.     

复方丹参滴丸对不稳定型心绞痛患者血浆内皮素和血小板α-膜颗粒蛋白的影响

目的观察复方丹参滴丸对不稳定型心绞痛患者的临床疗效及血浆内皮素（ET）和血小板α-膜颗粒蛋白（GMP-140）水平的影响。方法168例不稳定型心绞痛患者分为常规治疗组（79例）和复方丹参滴丸组（89例）。所有入选患者均接受硝酸酯类、美托洛尔（或钙拮抗剂）及阿司匹林治疗,复方丹参滴丸组在上述治疗基础上加用复方丹参滴丸10粒,每日3次,连用8周。观察统计两组治疗前1周和治疗结束后1周心绞痛发作次数及自拟的疼痛强度及持续时间记分值,检测治疗前后患者血浆ET和GMP-140水平的变化。结果复方丹参滴丸组和常规治疗组比较,治疗后疼痛发作频率、疼痛强度及持续时间记分均有明显减少,而复方丹参滴丸组的降低程度比常规治疗组明显（P〈0．05）。两组可改善不稳定型心绞痛患者心电图ST段的偏移,而复方丹参滴丸组的疗效比常规治疗组显著（P〈0．05）。两组治疗后血浆ET和GMP-140水平均明显减低,而复方丹参滴丸组的疗效比常规治疗组显著（P〈0．01）。结论复方丹参滴丸治疗不稳定型心绞痛患者疗效明显高于常规治疗,可能与改善血管内皮功能、抑制血小板聚集密切相关。     

保和丸联合辅酶A治疗脂肪肝的疗效对照研究

目的:研究保和丸联合辅酶A治疗脂肪肝的疗效.方法:以东宝肝泰联合辅酶A治疗为对照,对比两组的疗效率、生化指标和B超检查结果.结果:治疗组显效率为95%,明显高于对照组,其他各项指标也有明显差异性.结论:使用保和丸联合辅酶A治疗脂肪肝疗效较好且副作用小.     

外伤如意膏中龙脑含量测定

目的建立气相色谱法测定外伤如意膏中冰片含量的方法。方法采用WAXPEG-20M毛细管柱,柱温为140℃,进样口温度为230℃,检测器温度为250℃,流速为1．0mL／min。结果线性范围为0．05138～0．5138mg,平均回收率为96．0％,RSD=1．26。结论该方法简便、易操作,能有效控制该产品的质量。     

萸竹定眩丸治疗颈性眩晕短期疗效观察

目的:观察萸竹定眩丸治疗颈性眩晕的短期疗效。方法:将河南省中医院脊柱科门诊收治的80例患者随机分为对照组和观察组,各40例。对照组服用盐酸氟桂利嗪胶囊治疗,治疗组在服用盐酸氟桂利嗪胶囊基础上加服萸竹定眩丸治疗。每组疗程均为4周1个疗程,1个疗程后根据改良Macnab标准评估临床疗效。结果:治疗组40例中优4例,良28例,可6例,差2例,有效率80%(32/40);对照组中优1例,良21例,可8例,差10例,有效率55%(22/40),两组差异有统计学意义(P<0.05)。结论:盐酸氟桂利嗪胶囊治疗颈性眩晕能取得一定临床疗效,但盐酸氟桂利嗪胶囊联合萸竹定眩丸临床疗效更显著。     

五淋丸对大鼠异丙肾上腺素性缺血心肌的保护作用及其机制探讨

目的：观察五淋丸对异丙肾上腺素（Iso）诱发的大鼠心肌缺血的保护作用。方法：采用腹腔注射诱导大鼠致急性心肌缺血的动物模型。实验大鼠随机分为Iso模型组,阳性对照组和五淋丸大、中、小剂量组,观察各组大鼠心电图ST-iunction（J点）的位移、血清酶及血流动力学变化。结果：五淋丸大、中、小剂量组大鼠心电图J点的位移明显低于模型组（P〈O．05或P〈0．01）;血清肌酸激酶（（K）及乳酸脱氢酶（LDH）活性低于模型组（P〈O．01）;血流动力学指标：左心室收缩压（LVSP）、左心室舒张末压（LVEDP）、左心室等容期压力最大变化速率（土dp／dtmax）显著高于模型组（P〈O．05或P〈0．01）。结论：五淋丸对异丙肾上腺素所致大鼠缺血心肌具有保护作用,其机制可能与其改善心肌缺血大鼠心脏的舒缩功能有关。     

Effect of desogestrel 75 µg on headache frequency and intensity in women with migraine: a prospective controlled trial

Objective: In contrast with combined hormonal contraception, progestin-only contraception is not associated with an increase in venous thromboembolism or stroke. Women with migraine are at increased risk of ischaemic stroke. Several studies have reported a reduction in migraine frequency and intensity with desogestrel 75 µg, a progestin-only pill. At present the quality of data is limited by retrospective study designs, lack of control groups and small sample sizes. We present the first prospective nonrandomised controlled trial.

Methods: A total of 150 women with migraine visiting our clinic for contraceptive counselling were screened. The intervention group comprised women who opted for contraception with desogestrel (n?=?98); the control group comprised women who continued their usual contraceptive (n?=?36). Participants completed daily diaries for 90 days before the intervention and 180 days after the intervention.

Results: In the intervention group, we found improvements in migraine frequency (p?<?.001), migraine intensity (p?<?.001) and the number of triptans used (p?<?.001). These improvements were already significant after 90 days of desogestrel use (p?<?.001). Disability scores also decreased significantly. No improvement was seen in the nonintervention group.

Conclusion: These data demonstrate for the first time in a prospective controlled setting that daily use of the progestin desogestrel is associated with a decrease in migraine frequency, migraine intensity and pain medication use in women with migraine, with and without aura, who had previously been experiencing at least three days of migraine per month.

Trial registration: The study is registered in the University of Zürich database (www.research-projects.uzh.ch/unizh.htm).     

胃肠安丸治疗病毒性肠炎的临床研究

目的 探讨胃肠安丸在病毒性肠炎的治疗效果以及对患者可溶性白细胞介素-2(IL-2)和白细胞介素-10(IL-10)水平的影响.方法 选取于2013年10月到2014年10月期间本院收治的120例病毒性肠炎患者作为研究对象,将其随机分为观察组和对照组,每组60例.对照组接受常规治疗.观察组在对照组治疗的基础上给予胃肠安丸治疗.结果 观察组总有效率达到96.67％,对照组总有效为73.33％,两者差异具有统计学意义(P＜0.01).观察组患者止吐时间、退热时间以及止泻时间均显著低于对照组止吐时间、退热时间以及止泻时间,其差异具有统计学意义(P＜0.01).在恢复期,观察组患者的IL-10和IL-2水平均高于对照组患者的IL-10和IL-2水平,差异具有统计学意义(P＜0.01).结论 胃肠安丸治疗病毒性肠炎疗效显著,能够增强细胞免疫功能并且纠正免疫失衡,减少患者痛苦,促进患者恢复健康.     

Residual ovarian activity during oral steroid contraception

Steroid drugs with contraceptive properties have been available in the clinical setting for over four decades and are still subject to improvement. Estrogens, progestins and anti-progestins have been used alone or in various combinations, regimens and routes of administration to favour the balance between efficacy and undesirable effects. One of the most important changes in this respect is the gradual lowering of steroid dosage in commercially available contraceptives. Current steroid contraceptive pills still achieve the goal of suppression of pituitary-ovarian activity, but the margins for error are minimal. In this review the available data on modes of action and the effects on suppressing pituitary-ovarian activity by different forms of oral contraception are reassessed. Although pregnancy rates provide a crude measure of contraceptive efficacy, no benchmark for pituitary-ovarian inhibition is available to test the suppressive potential of contraceptive drugs. Consequently, many studies provide incomplete and/or incomparable results. For the further study of those forms of steroid contraception that rely predominantly on suppression of ovarian activity, prevention of dominant follicles selection should be the objective.